Kristen M. Sanfilippo, MD, MPHS

Address: 

• Hematology Division
  Mail Stop 8125-0022-01, Washington University, 660 South Euclid Avenue, St. Louis, MO 63110 (mail)
• Suite 1101 Wohl Hospital (office)

Clinical Interest: Venous thromboembolism; Cancer-associated thrombosis; Arterial thromboembolism; Anticoagulation; Antiphospholipid antibody syndrome; Pregnancy associated thrombosis; Thrombophilia; Hypercoagulable diseases

Research Interest: Venous thromboembolism; Cancer-associated thrombosis; Anticoagulant-related bleeding; Population health; Outcomes research; Big data

Research: 
Involvement in Clinical Trials and Grants: I have served as site PI for several multi-institutional trials, included NIH funded trials. In additional to those listed below, we are in the process of opening 2 large, randomized control trials to compare a long-acting injectable Factor XI antibody to DOAC or LMWH for patients with cancer-associated thrombosis.

1. CANVAS multi-institute, randomized trial, Role – Site PI Washington University 2016-2020. Trial comparing treatment of cancer-associated thrombosis with standard of care versus DOAC (pragmatic trial). Within top 5 accruing sites. Enrollment complete. Publication submitted.
2. EVE muti-institute, double-blind randomized trial, Role – Site PI Washington University 2018-current. Trial comparing apixaban 5mg twice daily to 2.5mg twice daily for long-term treatment of cancer associated thrombosis after 6 months. Enrollment complete. Data undergoing analyses.
3. TRUMPET multi-institutional observational trial, Role – Site PI St. Louis VA Medical Center 2018-2020. Observational study for patients with castrate resistant M0 or M1 prostate cancer. Enrollment complete.
4. PROPEL multi-institutional, double-blind, randomized trial, Role – Site PI St. Louis VA Medical Center 2018-2020. Study comparing abiraterone alone versus abiraterone/olaparib for treamtent of M1 castrate resistant prostate cancer. PI transferred to Dr. Eric Knoche so I could participate in the NIH Loan Repayment Program.
5. NIH ACTIV-4C double-blind, randomized trial, Role – Site PI Washington University 2021-current. Trial compares palcebo to low-dose apixaban for post hospital discharge in patients with OCVID-19. Enrollment closed 6/2022.

Biosketch

Education

• 2012-2011: MPHS (Master Population Health Science), Washington University School of Medicine, St. Louis, MO
• 2007-2003: MD, University of Missouri-Columbia, Columbia, MO
• 2003-1999: BS in Biology (magna cum laude), University of Missouri-Columbia, Columbia, MO

Post-Graduate Training

• 2013-2010: Hematology/Oncology Fellow, Washington University School of Medicine, St. Louis, MO
• 2010-2007: Internal Medicine Resident, University of Pittsburgh Medical Center, Pittsburgh, PA

Academic Positions

• 2023-present: Associate Professor, Hematology Division, Washington University School of Medicine, St. Louis, MO
• 2013-present: Staff Physician, Hematology/Oncology, John Cochran Veterans Administration Medical Center, St. Louis, MO
• 2023-2016: Assistant Professor, Hematology Division, Washington University School of Medicine, St. Louis, MO
• 2016-2013: Instructor of Medicine, Hematology Division, Washington University School of Medicine, St. Louis, MO

University & Hospital Appointments & Committees

• 2018-present: Barnes Jewish Hospital Warfarin Working Group
• 2017-present: Transfusion Review Committee, St. Louis VA Medical Center
• 2014-present: Barnes Jewish Hospital Clinical Panel, Hematology Formulary Working Group
• 2021: Development of BJC Guidance for Vaccine-Induced Immune Thrombotic Thrombocytopenia
• 2021: Pulmonary Embolism Response Team (PERT) Steering Committee
• 2020: Development of BJC Guidance for Thromboprophylaxis in Hospitalized Patients with COVID-19
• 2018-2017: Hematology Therapy Validation, Epic
• 2018-2016: Washington University Department of Medicine Leader, Development of Inpatient Epic

Board Certification

• 2014: American Board of Internal Medicine, Hematology
• 2013: American Board of Internal Medicine, Oncology
• 2010: American Board of Internal Medicine, Internal Medicine

Honors & Awards

• 2024-2022: American Society of Hematology, ASH Scholar Award
• 2012: American Society of Hematology, Clinical Research Training Institute
• 2011: American Society of Hematology, Abstract Award, Trainee
• 2003: Phi Beta Kappa National Honor Society
• 2002: Mortar Board Honor Society
• 2000: Phi Eta Sigma National Honor Society
• 2000: Golden Key National Honor Society

Editorial Boards

• 2022-present: Research and Practice in Thrombosis and Haemostasis

National Scientific Panels

• 2020-present: American Society of Hematology, COVID Coagulopathy Guideline Panel
• 2020-present: International Society on Thrombosis and Haemostasis, Hemostasis and Malignancy Subcommittee Co-Chair
• 2020-present: American Society of Hematology, Clinical Research Training Institute Faculty
• 2020-present: American Society of Hematology, Subcommittee on Clinical Trials

Professional Societies

• 2018-present: Hemostasis and Thrombosis Research Society
• 2017-present: International Society on Thrombosis and Haemostasis
• 2010-present: American Society of Hematology
• 2020-2010: American Society of Clinical Oncology

Selected Publications